MDC9, also known as meltrin γ, is a membrane-anchored metalloprotease. MDC9 contains several distinct protein domains : a signal sequence followed by a prodomain and a domain showing sequence similarity to snake venom metalloproteases, a disintegrin-like domain, a cysteine-rich region, an epidermal-growth-factor-like repeat, a transmembrane domain and a cytoplasmic domain. Here we demonstrate that MDC9 expressed in COS cells is cleaved between the prodomain and the metalloprotease domain. Further, when MDC9 was co-expressed in COS cells with amyloid precursor protein (APP695) and
INTRODUCTION
Metalloprotease\disintegrin\cysteine-rich proteins (MDCs, also called ' a disintegrin and metalloprotease ' or ADAMs) are membrane-anchored proteins with several domains including a metalloprotease domain, a disintegrin-like domain, a cysteinerich sequence, an epidermal growth factor-like sequence, a transmembrane domain and a cytoplasmic domain [1] . At least 21 members of the ADAMs family have now been identified and sequenced [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] ; together with snake venom metalloproteases they make up the reprolysin family of zinc metalloproteases. Members of the metzincin superfamily of proteolytic enzymes, including the reprolysin and matrix metalloprotease families, contain the distinctive zinc-binding consensus sequence HEXXH [12, 13] . However, only a subset of ADAMs, including ADAM 12 (' meltrin α '), contain this motif and are therefore considered to be potentially active metalloproteases. Protease activity has actually been demonstrated so far for only a few members of the ADAMs family, namely ADAM 17 (' TACE '), ADAM 12 and the Drosophila ADAM 10 homologue KUZ [7, 8, [14] [15] [16] [17] [18] [19] [20] .
Several lines of evidence suggest that metalloproteases are involved in the processing of the amyloid precursor protein (APP). APP is usually degraded within amyloid β (Aβ) by a putative α-secretase in normal brain ; a 90-100 kDa, soluble, non-amyloidogenic N-terminal fragment of APP (sAPP) is secreted from the cells [20] [21] [22] [23] [24] [25] . The α-secretase is suspected to be a metalloprotease and the α-secretase cleavage is activated by phorbol esters such as PMA and phorbol dibutyrate [26, 27] .
Abbreviations used : Aβ, amyloid β ; ADAM, a disintegrin and metalloprotease ; APP, amyloid precursor protein ; MMP, matrix metalloproteinase ; sAPP, secreted form of APP. 1 To whom correspondence should be addressed (e-mail cishiura!komaba.ecc.u-tokyo.ac.jp).
treated with phorbol ester, APP695 was digested exclusively at the α-secretory site in MDC9-expressing cells. When an artificial α-secretory site mutant was also co-expressed with MDC9 and treated with phorbol ester, APP secreted by α-secretase was not increased in conditional medium. Inhibition of MDC9 by a hydroxamate-based metalloprotease inhibitor, SI-27, enhanced β-secretase cleavage. These results suggest that MDC9 has an α-secretase-like activity and is activated by phorbol ester.
Key words : Alzheimer's disease, hydroxamate.
We report here that the metalloprotease domain of MDC9 (meltrin γ) is proteolytically active and that full-length MDC9 has an α-secretase activity for APP.
MATERIALS AND METHODS

Expression and purification of mMDC9s in COS cells
Full-length mouse MDC9 (mMDC9-FL) and metalloproteasedomain deletion mutant (mMDC9-∆MP) cDNA fragments were released from their stop codons by PCR by using site-directed mutagenesis primers. These DNA fragments were cloned into pSecTag (Invitrogen, San Diego, CA, U.S.A.). COS-7 cells were grown in Dulbecco's modified Eagle's medium with 4.5 mg\ml glucose and 10 % (v\v) fetal bovine serum at 37 mC in air\CO # (19 : 1). pSecTag\mMDC9-FL and pSecTag\mMDC9-∆MP were transfected into COS-7 cells by the electroporation method [28] . After 72 h of incubation, the transfected cells were collected and sonicated in buffer A [20 mM Tris\HCl (pH 7.5)\150 mM NaCl\5 mM EDTA\1 % (v\v) Triton X-100\0.1 % (v\v) Nonidet P40]. After centrifugation at 8000 g for 5 min, the protein concentration of the supernatant was determined with a DC protein assay kit (Bio-Rad, Richmond, CA, U.S.A.). The supernatant was diluted in 2iSDS buffer [125 mM Tris\HCl (pH 6.8)\30 % (v\v) glycerol\2 % (w\v) SDS\5 % (v\v) 2-mercaptoethanol\0.2 % Bromophenol Blue]. The samples were subjected to SDS\PAGE [10 % (w\v) gel] and then transferred to a PVDF membrane (Finetrap NT-32 ; Nihon Eido, Tokyo, Japan). The membrane was incubated overnight with anti-myc antibody (Invitrogen) at 4 mC and bands were revealed with a VECTASTAIN Elite ABC kit (Vector Laboratory, Burlingame, CA, U.S.A.) and a POD immunostain set (Wako, Osaka, Japan).
Purification and N-terminal amino acid sequence determination of mMDC9-FL
The mMDC9-FL was transfected into COS-7 cells, which were collected after 80 h and sonicated in buffer A. The homogenate was subjected to centrifugation, first at 8000 g for 10 min at 4 mC, then at 100 000 g for 30 min at 4 mC. The supernatant was applied to an Ni\nitrilotriacetate column (Qiagen, Hilden, Germany) equilibrated with buffer N [20 mM Tris\HCl (pH 7.5)\0.5 M NaCl\10 mM imidazole] and washed with 20 ml of 20 mM imidazole in buffer N. Proteins were eluted with 120 mM imidazole in buffer N (flow rate 1 ml\min) ; 2 ml fractions were collected. The fractions were dialysed overnight against buffer A and the protein concentrations of all fractions were determined with the DC protein assay kit. The fractions were diluted in 2iSDS buffer and samples were subjected to SDS\PAGE (10 % gel) and then transferred to a PVDF membrane. The membrane was incubated with anti-myc overnight at 4 mC and proteins were then revealed. The mMDC9-FL fraction was subjected to SDS\PAGE (10 % gel) and transferred to PVDF membrane (Trans-Blot2 ; Bio-Rad). The membrane was stained with 0.1 % Amido Black in 50 % (v\v) methanol\10 % (v\v) acetic acid. The protein band to be examined was cut out and washed with Milli Q. Amino acid sequences were determined with an Applied Biosystems model 492-140C amino acid sequencer (Foster City, CA, U.S.A.).
APP695 cleavage assay in vitro
Human APP695-WT (wild-type APP) with the p91023 vector was used to transfect COS-7 cells by the electroporation method [28] . After 72 h of incubation, the transfected cells were collected and sonicated in buffer A containing 10 µM trans-epoxysuccinyl--leucylamido-(4-guanidino)butane (' E-64 '), 10 µM leupeptin and 100 µM PMSF. After centrifugation at 8000 g for 5 min, the protein concentration of the supernatant (APP-lysate) was determined with a DC protein assay kit. Purified mMDC9-FL was incubated with APP-lysate (15 µg of protein) containing 5 mM MDC9 has an amyloid precursor protein α-secretase activity MnCl # or EDTA at 37 mC for 0, 2, 4, 8 and 24 h. Only APP-lysate for the negative control was incubated containing 5 mM MnCl # or EDTA at 37 mC for 24 h. The reaction was stopped with 2iSDS buffer and the mixture was then boiled at 100 mC for 5 min, subjected to SDS\PAGE (10 % gel) and then transferred to a PVDF membrane (Finetrap NT-32) . The transferred membrane was incubated overnight with anti-22C11 (Boehringer Ingelheim) or anti-Aβ1-16 antibodies [26] at 4 mC and proteins were then revealed.
Co-expression of mMDC9 and APP695s in COS cells
Various human APP695 cDNA fragments (APP-WT, APP-LAA and APP-∆α, artificial APP mutants) were constructed with the p91023 vector. We replaced the sequence HHQK of Aβ 13-16 with LHHAA to confer added resistance to α-secretory cleavage. We also constructed the deletion mutant APP-∆α lacking 19 residues from Arg'!" to Asp'"* (Aβ 5-23). The APP plasmid and mMDC9-FL or mMDC9-∆MP plasmid were used to transfect COS-7 cells with or without a hydroxamate-based metalloprotease inhibitor SI-27 (final concentration up to 20 µg\ml) by the electroporation method [28] . After 12 h of incubation, transfected cells were transferred to serum-free medium with or without PMA (final concentration 30 nM) and\or SI-27 (final concentration 20 µg\ml or as indicated). After an additional 24 h of incubation, the transfected cells were harvested, sonicated in buffer A and centrifuged at 8000 g for 5 min. The protein concentration of the supernatant was determined. The conditioned medium (8 ml) was concentrated by the addition of trichloroacetic acid and centrifuged at 10 000 g for 15 min. The precipitate was washed with diethyl ether\ethanol (1 : 1, v\v) and then dissolved in 300 µl of 2iSDS buffer. The samples were subjected to SDS\PAGE (10 % gel) and then transferred to a PVDF membrane. The transferred membrane was incubated with anti-APP antibodies overnight at 4 mC and proteins were revealed. The anti-APP antibodies used were anti-22C11 (Boehringer Mannheim), anti-Aβ1-16 [26] and anti-sAPPβ (T. C. Saido, unpublished work). The bands detected were quantified with an Imagemaster ver. 2.0 (Pharmacia). Figure 1(A) shows the mMDC9-FL and mMDC9-∆MP cDNA constructs. The immunoblot ( Figure 1B) indicates the molecular masses of mMDC9-FL (871 amino acid residues) and mMDC9-∆MP (734 residues ; ∆ 256-359) to be 108 and 92 kDa respectively. These sizes are slightly larger than those calculated from the primary sequences (95 and 80.3 kDa) and most probably reflect glycosylation, as in ADAM 12 polypeptides [29, 30] . mMDC9-∆MP was detected as a single band but mMDC9-FL revealed two bands (108 and 83 kDa). These results indicate that mMDC9-FL was cleaved between the prodomain and the metalloprotease domain but mMDC9-∆MP was not. We therefore conclude that this cleavage was due to MDC9 autolytic activity. We regard the lower 83 kDa band as being a cleavage product of the 108 kDa full-length band corresponding to the deletion of the prodomain (23 kDa ; 205 residue residues).
RESULTS AND DISCUSSION
Expression of mMDC9-FL and mMDC9-∆MP in COS cells
N-terminal amino acid sequence of mMDC9-∆Pro and APP cleavage assay in vitro
We attempted to determine the N-terminal sequence of the mMDC9 cleavage product (mMDC9-∆Pro). Figure 2(A) shows the SDS\PAGE patterns of proteins eluted from the Ni\ nitrilotriacetate column. The 83 kDa mMDC9-∆Pro was eluted from fractions 4-7 with approx. 60 mM imidazole. mMDC9-∆Pro was identified by immunoblot analysis with anti-myc antibody. The N-terminal amino acid sequence of the 83 kDa protein was determined as AVLPQTRYVELFIVVDKERY. This sequence agrees completely with mMDC9-FL residues 206-225 ( Figure 2B ). This cleavage occurred after the furin-like cleavage site (RRRR#!&-AVLP). Previous reports demonstrated that ADAM 12 is inactive until the prodomain is cleaved [18] and MDC9 is cleaved by recombinant furin between the prodomain and the metalloprotease domain [31] . We therefore conclude that full-length MDC9 can be cleaved and activated by autolysis or by furin-like protease in COS cells.
Next we tried to determine whether purified mMDC9-FL has an α-secretase activity. Figure 3 clearly demonstrates that mMDC9 had an α-secretase activity in itro. The purified mMDC9 (Figure 2A , fraction 5) was incubated with APP-lysate with or without MnCl # (Figure 3 , upper panel, lanes 4-8 and 9-13) at 37 mC. sAPPα was detected in lane 11 after 4 h with MnCl # and the amount was gradually increased (Figure 3, upper  panel, lanes 11-13) . In contrast, we could not detect sAPPα in the control lysates, even after 24 h (Figure 3, upper panel, lanes  2 and 3) . In the absence of MnCl # , however, sAPPα-like band(s) were detected (Figure 3, upper panel, lanes 6-8) . We regard these bands as a product formed by slightly active MDC9. In addition, we found that the amount of APP695-WT was decreased in a time-dependent manner ( Figure 3, lower panel) . The upper band of full-length APP695-WT was full-length endogenous APP770 in COS cell lysate, and this APP770 also decreased after 4, 8 and 24 h with MnCl # (Figure 3 , lower panel, lanes 11-13). These results strongly suggest that MDC9 had a metal-dependent α-secretase activity in itro.
α-Secretase activity of mMDC9
To investigate mMDC9 as a potential α-secretase, MDC9s (mMDC9-FL or mMDC9-∆MP) and APP analogues (APP-WT, APP-LAA or APP-∆α) were co-expressed in COS cells. APP expression in cell lysates and conditioned medium was evaluated by immunoblot analysis with anti-22C11 antibody. Secreted APPα and APPβ were specifically detected by using anti-Aβ1-16 or anti-sAPPβ antibodies respectively ( Figure 4A ). Densitometric quantification showed an increased secretion of the anti-Aβ1-16 immunoreactive product (sAPPα) from APP-WT by stimulation with phorbol ester ( Figure 4A , top panel, and Figure 4B ). This result agrees with previous reports that MDC9 is activated by PMA [31, 32] . The expression of MDC9 in COS cells also enhanced sAPPα secretion by phorbol ester treatment. Of three secretases, only α-secretase could be activated by phorbol esters. These results satisfy the necessary conditions for an α-secretase.
Next we transfected APP695-LAA cDNA in COS cells. We replaced the HHQK of Aβ 13-16 with LHHAA to confer greater resistance to α-secretory cleavage. Several reports have indicated that the secretion of sAPPα was triggered with PMA ( Figure 5A , upper panel, lanes 2 and 5) [26, 27] but the addition of SI-27 (20 µg\ml) suppressed the secretion of sAPPα ( Figure 5A, upper panel, lanes 3 and 6) . In contrast, the secretion of sAPPβ was inhibited by the treatment with PMA ( Figure 5A, lower panel, lanes 2 and 5) . In the presence of SI-27, however, sAPPβ secretion was increased ( Figure 5A , lower panel, lanes 3 and 6). As shown in Figure 5 (B), increasing concentrations of SI-27 (0, 0.2, 2.0, 8.0 and 20 µg\ml), had reciprocal effects on sAPPα and sAPPβ secretion ( Figure  5B ). The design of several metalloprotease inhibitors has been based on the structural requirements of the active site of metalloproteases for its substrates. Hydroxamate-based inhibitors have been used to inhibit metalloproteases. They are usually broad-spectrum matrix metalloproteinase (MMP) inhibitors and can also inhibit the shedding of membrane proteins [27] . SI-27 inhibited MMPs (IC &! values for MMP-3, MMP-2 and MMP-9 are 0.17, 0.036 and 0.090 µM respectively) as well as other metalloproteases (IC &! values for thermolysin and leucine aminopeptidase are 6.27 and 15 µM respectively) (A. Okuyama, unpublished work). Amour et al. [19] reported that hydroxamate derivatives strongly inhibited one ADAM, recombinant TACE. Although there is no evidence that SI-27 directly inhibits the ADAM family of metalloproteases, it is possible that SI-27 could inhibit ADAM.
Inhibition of sAPPα secretion by a metalloprotease inhibitor
In the present study we examined the role of MDC9 in the regulated α-secretion of APP. The MDC9 expressed in COS cells increased the secretion of basal sAPPα ( Figure 4A , lanes 1 and 3) and enhanced sAPPα secretion in the PMA-treated condition ( Figure 4A, lanes 2 and 4) . The addition of SI-27 inhibited the MDC9-induced secretion of sAPPα. A previous report demonstrated that the stimulation of sAPPα release by PMA was not observed in ADAM 17 knock-out cells [20] . However, basal sAPPα secretion was still observed, indicating that ADAM 17 is not α-secretase but has a similar specificity to that of α-secretase. The mRNA content of ADAM 17 is low in human adult brain [7] , but the mRNA for MDC9 is ubiquitously expressed in human tissues. In conclusion, we believe that MDC9 is an α-secretase responsible for processing APP.
